Redeye concludes that Q2 came in softer than Redeye had estimated, both in terms of lower sales and ...
Redeye comments on Flexion Mobile's Q2 2024 report, which was in line with our expectations.
Redeye saw a Q2 report showing sales slightly below our estimates, with a total growth of 31% for th...
Redeye comments on Thunderful Group’s Q2’24 report, which came in better than expected in terms of s...
Redeye sees a stable Q2 report from Teneo AI, with solid customer intake being the highlight.
Redeye states that Q2 came in weaker than it had expected, although the reason continues to be a ver...
Redeye reiterates its valuation following the Q2 2024 report, which was stronger than our expectatio...
Taaleri's Q2 2024 results were well above LSEG Data & Analytics consensus and our expectations, main...
'24e-'26e sales up 3-2% Volume growth to pick up in H2 Revised FVR of SEK 25-40 (20-35) Q2: Strong ...
Solid sales but slightly higher opex EBIT revised down by 4.
Lyckegård publicerade den 20 augusti år 2024 bolagets delårsrapport för det andra kvartalet år 2024.
Redeye returns with a more detailed take on the Q2 report, and we make some estimate changes that pu...
Överenskommelser har nåtts med majoriteten av obligationsinvesterarna.
Pharma Equity Group (“PEG” or “the Company”) presented a Q2-report characterized by further advancem...
Risk för lägre försäljning än vad marknaden estimerar, men marginalerna borde vara bättre än väntat.
Redeye concludes that the reported figures were overall stronger than we had forecasted.
Redeye sees the Q2 report coming in below estimates for both sales and EBIT.
Sales and profitability were weaker than expected; however, Redeye views this half-year period as be...
Organic growth of 66%, +14pp vs. ABGSCe ARPPU +11% vs.
Taaleri reported Q2 EBIT of EUR 4.4m, clearly above LSEG Data & Analytics consensus at EUR 3.
